StockData
Altimmune, Inc. logo

Altimmune, Inc. (ALT) KPIs and segments

ALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/30
$1.61−0.32 (-16.58%)

Close on Nov 12, 2026Market cap $313.17MP/E –Yield –

KPIs & segments

Operating metrics and segments that drive Altimmune's business

Altimmune's revenue by segment, product and region, plus the counts and sizes it tags in its 10-K and 10-Q filings (XBRL). Each figure links to the filing it came from. A fuller KPI sheet built from earnings releases and presentations is on the way. See the segment tables for a trailing-twelve-month view, or how companies compare on operating metrics.

The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.

Add to chartMetric
Q4 2018
Q3 2018
Q2 2018
Q4 2017
Q3 2017
Q2 2017
Grant($M)
2.582.632.412.804.573.03
License Revenue($M)
0.000.000.000.000.030.00

Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).

Methodology and excluded metrics
  • Core rows come from the segment and revenue-disaggregation notes of 10-K and 10-Q filings (XBRL), linked to each filing. Fourth-quarter figures are the fiscal year less the first nine months (shown in italic).

Data updated 2019-04-01.

See a number that looks wrong?